- Medicine Name: Qelbree
- Generic Name: Viloxazine
- Dosage Form & Strength: Capsules: 100 mg, 150 mg and 200 mg
- Manufactured By: Supernus Pharmaceuticals, Inc.
Qelbree (Viloxazine 100 mg, 150 mg and 200 mg) is a selective norepinephrine reuptake inhibitor widely used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
Recommended Dosage: Administer this medicine orally with or without food. Do not chew, cut, or crush the capsules. Swallow capsules, or open them and sprinkle the whole contents over a tablespoonful or teaspoonful of pudding/applesauce. Consume the food mixture in its entirety, without chewing, within 15 minutes for pudding, or within a couple of hours for applesauce; avoid storing it for future use.
Pediatric patients: The recommended starting dosage of Qelbree capsules for pediatric patients 6-11 years of age is 100 mg by mouth (orally) once daily. Dosage can be titrated in increments of 100 mg at weekly intervals to the maximum dosage of 400 mg once in day, on behalf of response and tolerability. The recommended starting dosage for pediatric patients 12-17 years of age is 200 mg by mouth (orally) once a day. After 7 days (1 week), dosage can be titrated by an increment of 200 mg to the maximum dosage of 400 mg once in a day, on behalf of response and tolerability.
Adult patients: The recommended starting dosage of Qelbree capsules for adults is 200 mg orally once a day. Dosage can be titrated in increments of 200 mg weekly to the maximum dosage of 600 mg once a day, on behalf of response and tolerability. Pharmacological treatment of attention deficit hyperactivity disorder may be required for extended periods. Periodically reevaluate the long-term use of Qelbree and adjust dosage as required.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.